x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Base to Base Biotech

The Base to Base Biotech podcast is a weekly look at what"s happening in the world of biotech, with interviews with biotech leaders around the world.Whether it"s a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.Base to Base is an Ayr Coastal Media Ltd production.

health & fitness medicine

All Episodes

47:48

Base to Base biotech podcast 22: A new treatment for...

Base to Base Biotech ·

2025/08/15

This week, we talk about new treatments for wet dry age-related macular degeneration (AMD) with Judith Greciet, CEO of PulseSight Therapeutics, and there’s a conversation with Maite Agüeros, CEO and co-founder of InnoUp Farma about, among other things, peanut allergies.Interview times: 03:24 PulseSight 20:43 InnoUpTackling dry AMDPulseSight Therapeutics SAS, an ophthalmology biotech company developing non-viral vectorised therapies with minimally-invasive delivery technology, recently announced the

en

42:48

Base to Base biotech podcast 21: Elix drug discovery...

Base to Base Biotech ·

2025/08/08

This week, we talk about drug discovery with Shinya Yuki, co-founder and CEO of Elix Inc., and Teresa Whalen, CEO of CytoAgents, about CAR-T therapies, cytokine release syndrome, and the FDA. Interview times: 03:53 Elix 20:58 CytoAgentsElix drug discovery platformAI drug discovery company Elix, Inc. and the Life Intelligence Consortium (LINC) have announced that for the first time in the world, an AI drug discovery platform has been commercialized that incorporates multiple AI models trained using

en

53:35

Base to Base biotech podcast 20: Terumo BCT boosts...

Base to Base Biotech ·

2025/08/01

This week, our conversations are with Wenyan Leong, director of APAC commercial and global strategic partnerships for cell and gene therapies at Terumo Blood and Cell Technologies, and Morten Graugaard, CEO of Orbis Medicines.Interview times: 04:01 Terumo BCT 24:52 Orbis MedicinesTerumo Blood and Cell Technologies shows integrated 3-in-1 CAR-T workflow with quantum platformTerumo Blood and Cell Technologies, (Terumo BCT), a medical technology company, recently published a new protocol in a paper

en

39:25

Base to Base biotech podcast 19: Nipro on dialysis...

Base to Base Biotech ·

2025/07/25

This week’s podcast is sponsored by Nipro.This week, our conversations are with Jesus Garcia, Nipro Product Manager Water Treatment, on Nipro ’s recently-launched product LiniXia, a reverse osmosis (RO) system that ensures safe and pure water for every dialysis session, and on the future of biologics manufacturing with cell-free protein synthesis with LenioBio CEO André Goerke.Interview times:05:16 Nipro 15:52 LenioBioNIPRONipro Medical Europe is part of Nipro Corporation Japan, a leading global

en

50:39

Base to Base biotech podcast 18: NETs and AI to...

Base to Base Biotech ·

2025/07/18

This week, we have conversations with Eduardo Bravo, CEO of Citryll, and Dermot Tierney, COO of AMPLY Discovery.Interview times:02:53 Citryll21:56 AMPLY DiscoveryCitryllCitryll’s recent Series B financing of €85m at the end of last year is helping to advance its first-in-class therapy targeting neutrophil extracellular traps (NETs).Discovered in 2004, NETs are web-like structures released by white blood cells that are now understood to be fundamental drivers of inflammation - yet they've never been

en

54:37

Base to Base biotech podcast 17: Silico nanoparticle...

Base to Base Biotech ·

2025/07/11

This week, our subjects are a silica nanoparticle gene delivery system in a conversation with Nigel Theobald, CEO of N4 Pharma, and a point-of-care diagnostics system for urinary tract infections developed by Welsh company Llusern Scientific. We spoke with the company's co-founder and CEO, Dr Emma Hayhurst.Interview times:03:00 N4 Pharma 24:45 Llusern ScientificN4 PharmaN4 Pharma is a UK biotech company developing a silica nanoparticle gene delivery system called Nuvec.Nuvec is being used to enable

en

73:19

Base to Base biotech podcast 16: Domain Therapeutics,...

Base to Base Biotech ·

2025/07/04

This week, we have conversations with Sean MacDonald, CEO of Domain Therapeutics, Carina Kern, CEO and founder of LinkGevity, and Nadia Harhen, general manager of AI Simulation at SandboxAQ. Interview times:03:41 Domain Therapeutics 27:14 SandboxAQ48:04 LinkGevityDomain TherapeuticsDomain Therapeutics is delivering breakthrough GPCR-targeting therapies in immuno-oncology and inflammation.Domain recently shared first-in-human results for EP4 antagonist DT-9081 (tumour-growth inhibition + clear

en

55:17

Base to Base biotech podcast 15: Bio-convergence and...

Base to Base Biotech ·

2025/06/27

This week, we have conversations with Phil L'Huillier, CEO of Scancell, and Shai Melcer, head of Israel’s National Bio-Convergence Program.Interview times:03:25 Scancell 28:04 National Bio-Convergence ProgramScancellScancell recently announced a partnership with the UK’s NHS Cancer Vaccine Launch Pad, enabling fast-tracked access for melanoma patients.The company’s DNA off-the-shelf cancer vaccine (iSCIB1+) is addressing a critical unmet need in advanced metastatic melanoma. It is currently in phase

en

54:00

Base to Base biotech podcast 14: How to build...

Base to Base Biotech ·

2025/06/20

This week, we have conversations with Peter Nolan, CEO of BlackFinBio, and Kim Kraemer, CEO and founder of Waterhouse Brands.Interview times:01:57 BlackFinBio 19:36 Waterhouse BrandsBlackFinBioBlackfinBio is a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases.Its pipeline comprises BFB-101, a clinical stage AP4B1 replacement adeno-associated virus (AAV) gene therapy for spastic paraplegia 47 – an ultra-rare genetic neurological disease for

en

46:09

Base to Base biotech podcast 13: Syngene commits to...

Base to Base Biotech ·

2025/06/13

This week, we have conversations with Dr Peter Tummino, president of R&D at Nimbus, and Alex Del Priore, senior vice president, manufacturing at Syngene International Limited.Interview times:02:00 Syngene 20:27 Nimbus TherapeuticsNimbus TherapeuticsNimbus Therapeutics is perhaps best known for two high-profile deals – Gilead’s $1.2bn acquisition of its NASH program and Takeda’s $4bn acquisition of its TYK2 candidate for psoriasis. NASH and TYK2 are well-known targets that many companies have

en

40:31

Base to Base biotech podcast 12: CLS boosts drug...

Base to Base Biotech ·

2025/06/06

This week, our guests are Ben Cliff, CEO of UK-based CRO, Concept Life Sciences, and Ravi Rao, chief medical officer of Sitryx.Interview times01:12 Sitryx 19:40 CLS Concept Life SciencesConcept Life Sciences (CLS), a provider of drug discovery, development, and manufacturing services to the global pharma and biotech sector, recently announced an investment into its drug discovery capabilities.CLS is the UK’s biggest independent CRO, employing over 250 people, and with a corporate heritage spanning

en

54:26

Base to Base biotech podcast 11: Turning cancer into...

Base to Base Biotech ·

2025/05/30

This week, we have a conversation with Ben Zeskind, CEO and co-founder of Immuneering, and a discussion with Tasso Inc.’s co-founder and CEO Ben Casavant.Interview times:01:27 Tasso 27:25 ImmuneeringImmuneeringThere is no cure for HIV, yet many people with the virus now live long, healthy lives – thanks to available medicines that prevent disease progression with minimal side effects, treating HIV almost like a chronic condition.So why don’t we treat cancer the same way?Curing cancer is seen as the

en

42:47

Base to Base biotech podcast 10: 3D printing human...

Base to Base Biotech ·

2025/05/23

This week, we have a conversation with Vidmantas Šakalys, CEO of bioprinting company Vital3D Technologies, and a chat with Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx, another of the companies that attended the American Association for Cancer Research (AACR) annual meeting in Chicago recently.Interview times:01:47 Vital3D Technologies20:46 AOA DxVital3D TechnologiesLithuanian company Vital3D Technologies is developing 3D bioprinting technology aimed at bridging the organ supply-demand gap by

en

68:38

Base to Base biotech podcast 9: Microbiotica,...

Base to Base Biotech ·

2025/05/16

This week, we’re talking to some of the companies that attended the American Association for Cancer Research (AACR) annual meeting in Chicago.We have interviews with Microbiotica, 1Cell.Ai, and Tessellate Bio.Interview times:01:55 Tessellate Bio17:02 1Cell.Ai (formerlyOneCell Diagnostics)44:04 MicrobioticaMicrobioticaMat Robinson, SVP Research at Microbiotica, is one of our guests.Microbiotica presented new data at AACR about the microbiome and the mechanism of action of MB097, a clinical-stage drug

en

43:10

Base to Base biotech podcast 8: ‘Photoshop for...

Base to Base Biotech ·

2025/05/09

This week on the podcast, we have a conversation with Elise de Reus, the co-founder of Cradle, a biotech startup that is revolutionising protein design, and a chat about improving hospital operations with Proximie’s CEO and founder, plastic surgeon Dr. Nadine Hachach-Haram.Interview times:01:55 Proximie 21:40 CradleProximieProximie has built the only cloud OS for intelligent operating rooms. With 800 operating rooms across the US and UK utilizing Proximie, the company is rapidly growing its US

en

47:39

Base to Base biotech podcast 7: The DSCSA deadline...

Base to Base Biotech ·

2025/05/02

This week on the podcast, we have a conversation with Tim Tinnel, executive vice president/chief operating officer of Intelliguard, talking about – among other things – the looming Drug Supply Chain Security Act (DSCSA) deadline, and Jorge Jorge Santos da Silva, founder and CEO of MoonLake Immunotherapeutics, about its Nanobody programme.Interview times: 01:42 MoonLake Immunotherapeutics 25:24 IntelliguardMoonLake ImmunotherapeuticsLater this year, MoonLake Immunotherapeutics will be announcing its

en

34:10

Base to Base biotech podcast 6: Persica...

Base to Base Biotech ·

2025/04/25

This week on the podcast, we have a conversation with Steve Ruston, CEO of Persica Pharmaceuticals, about treating chronic low back pain, and with Monika Paulė, CEO and co-founder of Caszyme.Interview time stamps:Times: 01:40 Caszyme 16:04 Persica PharmaceuticalsPersica PharmaceuticalsPersica is developing a potentially transformative non-opioid treatment for chronic low back pain (cLBP) with some interesting phase 1b data.Chronic low back pain is a problem that affects millions of people, many of

en

54:26

Base to Base biotech podcast 5: Vitalant’s vital role...

Base to Base Biotech ·

2025/04/18

This week on the podcast, we have a conversation with Vitalant’s Kevin Land, executive medical director, Biotherapies, and VP of Clinical Services, and Becky Cap, SVP, Biotherapies; and chat with Brainomix CEO and co-founder Michalis Papadakis about making a difference in getting faster treatments for stroke victims.Times: 01:52 Brainomix 21:44 VitalantVitalantVitalant, which used to be known as Blood Systems Inc., is a US nonprofit organization that collects blood from volunteer donors and provides

en

50:52

Base to Base biotech podcast 4: A new class of...

Base to Base Biotech ·

2025/04/11

This week on the podcast, we have conversations about hiring in the lifesciences industry in 2025, and about a potential new class of synthetic therapeutics.Interview times: 02:49 ThirdLaw Molecular 21:14 Occam GlobalThirdLaw MolecularThirdLaw Molecular is a biotech company that has pioneered the discovery and development of Spiroligomer molecules – a groundbreaking new platform for targeted drug discovery.The company is designing and synthesizing libraries of billions of Spiroligomer-based

en

52:29

Base to Base biotech podcast 3: Nanoparticles and...

Base to Base Biotech ·

2025/04/04

Interview timestamps: 02:20 Satellos 26:00 EVŌQ NanoAntibiotic-resistant infections are a top 10 global health threat demanding urgent innovation.A US-based nanotech company, EVŌQ Nano, has developed a novel nanoparticle that destroys bacteria from the inside – without triggering antimicrobial resistance (AMR).The nanoparticle is already in development for an inhaled therapeutic for Cystic Fibrosis patients, as well as for antimicrobial medical devices and treatment of the surface of textiles. It is

en

42 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown